At the last meeting of the European Society of •^•Pneumology, where European audits of asthma therapy were presented, 13 it was suggested that: 1) asthma is generally underdiagnosed, and 2) there are regional trends and sometimes big differences in the approach to treatment of chronic asthma, especially in France.
About 90 percent of the 128 French respondents, who are specialists in pulmonary medicine or allergy, see asthma patients.
In the treatment of severe episodes of acute asthma, inhaled beta-agonists, parenteral steroids and parenteral aminophylline head the sequence of therapy (Table 1) . Parenteral beta-agonists are in fourth position. Anticholinergic drugs are not considered firstline therapy of acute asthma.
For treatment of chronic asthma, first choice for regular maintenance in adults in Europe is inhaled beta-agonists (Table 2) . They are always used for longterm therapy by 43 percent of the European respondents, but by only 25 percent of the French physicians. French physicians favor therapy with oral theophyllines, whereas the British physicians do not like them: oral theophyllines are used by 42 percent of the French, but only by 2 percent of the British. Inhaled cromoglycate occupies the third position in France, while inhaled steroids, are the third choice in Europe as a whole.
In all countries, the top four drugs for long-term treatment of asthma are the same. Current practice for physicians, in most European countries, is the "BAC" regimen (B = beta-agonists, A = aminophylline, C = corticosteroids). In France, the "ABC" regimen is preferred, and with inhaled cromoglycate being used more frequently than corticosteroids.
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The survey of maintenance treatment showed little difference between the approaches to adults and children in Europe (Table 3) , with the exceptions of cromoglycate, which scores higher in children than in adults, and of inhaled corticosteroids, which scored quite low in children, especially in France. In comparing the practices in France, the United Kingdom and Germany ( Table 4 ) it appears that: 1) the French score for inhaled therapy was low for beta-agonists compared to the United Kingdom and Germany, and was very low for inhaled steroids compared to United Kingdom; 2) oral routes are preferred for children in France; the score for oral theophyllines and oral ketotifen was high (Table 5) .
The lower dosage of inhaled beta-agonists and of inhaled steroids in France may explain the country's greater use of oral theophyllines in the long-term therapy of chronic asthma.
The use of desensitization differs in Europe as to the type of doctor, the region and the age of asthmatic patients. In adults and children, most of the specialists use desensitization sometimes, but the allergy specialists use it often. In adults, only 5 percent of all respondants use desensitization always, but this rises to about 10 percent in France, especially for children.
In summary, asthma treatment in France differs from that of other European countries in: 1) greater use of desensitization and antiallergic drugs in allergic asthma and young patients; 2) preferential use of theophyllines in maintenance bronchodilator therapy; 3) lower use of inhalation therapy and preference for oral medications; 4) lower use of corticosteroids, especially of inhaled steroids.
COMMENTS
Clearly, the methodology of the European Audit of Asthma Therapy makes the data somewhat difficult to interpret because of the heterogeneity of the respondents. In France, these were largely pulmonary specialists or physicians involved in allergy. We need more information on the practices of general practitioners and pediatricians who diagnose and treat asthma. Surveys of randomly chosen samples of the practicing community with special examination of the nonrespon- We do not know yet if the differences in the French management of asthma lead to differences in mortality, morbidity, hospital admissions and quality of life for asthmatic patients. It seems that the regional trends depend upon several considerations, such as: 1) the relative proportion in each country of general practitioners, chest physicians, allergists and pediatricians involved in treating asthma, which may depend upon demographic and economic differences in each region; 2) the official (from medical school), and non-official, (mainly from firms), postgraduate teaching programs.
These two points could lead to differences in diagnostic and therapeutic approaches to asthma. The diagnosis may differ depending upon the methods used for detecting allergy, bronchial hyperreactivity, bronchial inflammation and chronic obstructive bronchial disease. Differences in the methods used for diagnosis may influence the therapeutic approach, influencing the choice of immunotherapy and antiallergic drugs, atropine-derivatives, and doses of bronchodilators and corticosteroids.
In France, a population of 55 million is served by about 69,000 physicians involved in private practice. Of these, 46,000 are general practitioners, and about 700 are chest physicians, a category that is increasing disproportionately to the total number of physicians (Table 6 ). The number of consultations for asthma is increasing more rapidly than for other diagnoses. Consultations for asthma represent about 20 percent of the activity of chest physicians, and less than 1 percent for other physicians. If we consider sales of antiasthmatic drugs (Fig 1) , theophyllines represent more than 50 percent of the total sales in France. Sales of In conclusion, possible reasons for the differences in treatment, as suggested by the Audit, are as follows: 1) more allergists are involved in the management of asthma in France than in other European countries; 2) many French physicians are still concerned about the toxicity of beta-agonists and steroids; 3) high-dose preparations of inhaled steroids are not yet available in France; 4) historic preference for rectal and oral routes of treatment.
All of these data must be confirmed by another survey conducted on the basis of a randomized distribution of questionnaires among chest physicians, allergists, pediatricians and general practitioners, in order to obtain more information on their habits in diagnosing and treating asthma. To understand the possible causes for differences between countries, we have to take into account the influence of differences in physician sampling, in the modalities of diagnosing asthma, in the graduate and postgraduate teaching of clinical pharmacology, and the availability and promotion of drugs by pharmaceutical companies. We will then be able to understand more precisely the reasons for differences in treatment and perhaps ultimately affect morbidity and mortality of asthma.
